Mitochondrial targeted therapies in MAFLD

Area of Science:

• Hepatology
• Mitochondrial Biology
• Metabolic Diseases

Background:

• Metabolic dysfunction-associated fatty liver disease (MAFLD) is characterized by excessive fat accumulation in liver cells, unrelated to alcohol.
• Mitochondrial dysfunction is a key factor in MAFLD pathogenesis, contributing to oxidative stress and inflammation.
• Mitochondria are dynamic organelles crucial for cellular energy metabolism.

Purpose of the Study:

• To systematically review the role of mitochondria-targeted therapies in MAFLD.
• To evaluate current therapeutic strategies for MAFLD concerning mitochondrial dysfunction.
• To explore future directions and clinical implications of these therapies.

Main Methods:

• Systematic review of literature on MAFLD and mitochondrial dysfunction.
• Analysis of molecular mechanisms linking mitochondrial dysfunction to MAFLD.
• Evaluation of emerging and established therapeutic approaches.

Main Results:

• Mitochondrial dysfunction exacerbates MAFLD through oxidative stress and inflammation.
• Targeting mitochondria offers potential therapeutic avenues for MAFLD.
• Understanding molecular pathways is crucial for developing effective treatments.

Conclusions:

• Mitochondria-targeted therapies hold promise for treating MAFLD.
• Further research into molecular mechanisms can guide novel therapeutic development.
• Clinical translation of these therapies is a critical future step.